Pre-operative Immuno-Nutrition in Radical Cystectomy
NCT06355518 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260
Last updated 2024-04-09
Summary
This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer. Patients receiving preoperative immunonutrition will be compared to controls receiving a standard high-calorie, high-protein oral nutritional supplement.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Immunonutrition
This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
- DIETARY_SUPPLEMENT
-
Standard Oral Nutritional Supplement
This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
Sponsors & Collaborators
-
IRCCS Ospedale San Raffaele
collaborator OTHER -
Fondazione IRCCS Policlinico San Matteo di Pavia
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-30
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy
NCT02345473 ·Status: COMPLETED
-
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
NCT06337305 ·Status: COMPLETED
-
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy
NCT01827618 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Prophylactic Antibiotics in Cystectomy With Diversion
NCT06190197 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
NCT06167356 ·Status: RECRUITING
-
Protocol of the Italian Radical Cystectomy Registry
NCT04228198 ·Status: UNKNOWN
-
Predictive Role of Microbiome in Patients With Urothelial Carcinoma
NCT06675656 ·Status: NOT_YET_RECRUITING
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
Intravesical BCG: is the Urinary Bladder Ready to Receive it
NCT05335512 ·Status: NOT_YET_RECRUITING
-
Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy
NCT03049410 ·Status: COMPLETED ·Phase: NA
-
Prospective Multicentric Evaluation of a Bladder Preservation Strategy
NCT01093066 ·Status: TERMINATED ·Phase: PHASE2
-
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
NCT02968732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
NCT05226117 ·Status: COMPLETED ·Phase: PHASE2
-
Investigator Grant (IG) 2022 27746
NCT06341478 ·Status: RECRUITING ·Phase: NA
-
Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy
NCT03307200 ·Status: COMPLETED
-
URO-BCG-4 : Bladder Tumors Immunotherapy
NCT00213655 ·Status: COMPLETED
-
Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic
NCT04770974 ·Status: UNKNOWN
-
Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
NCT04672317 ·Status: UNKNOWN ·Phase: PHASE2
-
Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
NCT03529890 ·Status: UNKNOWN ·Phase: PHASE2
-
Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
NCT02699853 ·Status: TERMINATED ·Phase: NA
-
Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
NCT04617756 ·Status: RECRUITING ·Phase: PHASE2
-
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00191711 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Single-arm, Multicenter Phase II Clinical Study: Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
NCT05356351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Detection of Disease in the Upper Tract
NCT05349812 ·Status: WITHDRAWN
-
Enhanced Recovery After Radical Cystectomy Study
NCT02328417 ·Status: COMPLETED